Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

92.84 +1.38 (+1.51%)
Streaming Delayed Price Updated: 12:39 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
News headline image
Former Surgeon General Slams RFK Jr. Over mRNA Cuts, Says US 'Conceding To China,' 2 Million Lives At Risk ↗
Adams warns cutting funding for mRNA vaccine research will cost lives, derail medical progress, and give China an advantage. 
Via Benzinga
News headline image
Breaking Down BioNTech: 12 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
These Analysts Revise Their Forecasts On BioNTech After Q2 Results ↗
 
Via Benzinga
BioNTech Gets Price Target Bumps From BofA, Clear Street After Strong Q2, Oncology Pipeline Push ↗
Via Stocktwits
News headline image
BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth ↗
BioNTech beat Q2 estimates with higher COVID vaccine revenue and reaffirmed 2025 guidance. 
Via Benzinga
News headline image
Earnings Scheduled For August 4, 2025 ↗
 
Via Benzinga
News headline image
A Look Ahead: BioNTech's Earnings Forecast ↗
 
Via Benzinga
News headline image
BioNTech SE (NASDAQ:BNTX) Q2 2025 Earnings: Revenue Surges 68.5%, Losses Narrower Than Expected ↗
BioNTech Q2 2025 earnings beat revenue estimates with $255.99M, narrowing losses to -$1.57 EPS. Shares rose 2% pre-market as oncology pipeline advances. 
Via Chartmill
Topics Earnings
News headline image
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave
In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Moderna's Key Patent Win Overshadowed By Gloomy Outlook ↗
Moderna beat Q2 earnings and revenue estimates, narrowed its annual forecast, won a key patent case, and plans to cut 10% of its global workforce. 
Via Benzinga
Topics Intellectual Property
News headline image
Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion ↗
Bristol Myers beat Q2 sales expectations but cut its 2025 EPS forecast as strategic charges and legacy product declines weighed on earnings. 
Via Benzinga
News headline image
Where Will Pfizer (PFE) Be in 5 Years? ↗
The big drugmaker should be even bigger over the next five years despite facing a patent cliff. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Robert Kennedy Jr Blasts Vaccine Injury Compensation Program: 'Devolved Into A Morass Of Inefficiency, Favoritism, And Outright Corruption' ↗
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is pledging a major overhaul of the National Vaccine Injury Compensation Program (VICP), describing the system as fundamentally broken... 
Via Benzinga
News headline image
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Announces Ryan Richardson to Step Down from the Management Board
From BioNTech SE
Via GlobeNewswire
News headline image
Breaking Down BioNTech: 12 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Why Is AbbVie Stock Trading Higher On Thursday? ↗
AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data. 
Via Benzinga
News headline image
FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months ↗
Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 vaccine patent dispute. 
Via Benzinga
Topics Intellectual Property
News headline image
AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment ↗
Via Benzinga
News headline image
Ex-Pfizer Exec Pulled Into House Probe Over Alleged COVID Vaccine Delay Through 2020 Election ↗
The committee cited remarks allegedly made by Philip Dormitzer at GSK, claiming that Pfizer’s top R&D leaders delayed clinical trial progress to avoid releasing results before the 2020 election. 
Via Stocktwits
Topics Government Law Enforcement
News headline image
Expert Outlook: BioNTech Through The Eyes Of 11 Analysts ↗
 
Via Benzinga
News headline image
5 Stocks To Ride The German Market Rally ↗
 
Via Benzinga
News headline image
Accenture To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CureVac N.V. (Nasdaq - CVAC), Know Labs, Inc. (NYSE American - KNW), Volato Group, Inc. (NYSE American - SOAR), Heliogen, Inc. (OTC - HLGN)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Market Monitor News June 13 (Oracle UP - Gamestop DOWN) ↗
U.S. stocks edge higher as inflation cools, Oracle soars on AI growth, and markets brace for Israel-Iran conflict escalation. 
Via Chartmill
Topics Artificial Intelligence Economy
News headline image
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal ↗
BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline. 
Via Benzinga
News headline image
BioNTech To Acquire CureVac In All-Stock Deal Valued At $1.25B: Retail Sees Breakthrough In Cancer Treatment ↗
Under the terms of the deal, each CureVac share will be exchanged for approximately $5.46 in BioNTech American depositary shares. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.